Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 231

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 231
---
 be conducted in accordance with cGCP requirements and the applicable
regulatory requirements and the ethical principles having their origin in the Declaration of Helsinki.

If we fail to comply with
applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals,
product recalls, seizure of products, operating restrictions and criminal prosecution.

We have several operating
leases for offices, laboratories and clinic. Our offices are located in London, New York and Hong Kong.

See “Facilities”
above.

History and Development of the Company

Aptorum was incorporated under
the laws of the Cayman Islands on September 13, 2010. As of the date hereof, our authorized share capital is $100,000,000.00 divided into
9,999,996,000,000 Class A Ordinary Shares with a nominal or par value of $0.00001 each and 4,000,000 Class B Ordinary Shares with a nominal
or par value of $0.00001 each.

The Company now focuses all
of its efforts on R&D and therefore no longer performs any therapeutic services. While the Company may commence therapeutic services
in the future, as of December 31, 2024 and the date hereof, it only operates in one segment.

Aptorum is not a Chinese operating
company. Aptorum is a Cayman Islands holding company with operations conducted through our subsidiaries and the variable interest entity
(VIE). We have determined that we have one VIE: Libra, according to the U.S. GAAP. In accordance with ASC 810, we concluded that we are
not the primary beneficiary of Libra and therefore we do not consolidate its financial statements into ours. Previously, we determined
that we were the primary beneficiary of another VIE, Mios Pharmaceuticals Limited; however, Mios was dissolved in 31 October 2024 and
therefore we no longer maintain any ownership over such entity. Our corporate structure is based on the equity ownership and control we
have over our subsidiaries. Our corporate structure was not set up to be used to provide investors with exposure to foreign investment
in China-based companies where Chinese law prohibits direct foreign investment in the operating companies. Foreign investment can be made
directly into the VIE, however, your investments into Aptorum are made into the Cayman Islands holding company, not our VIE, and you may
never own any equity into the VIE or any other subsidiary.

APTUS CAPITAL